Citi Sees Positive Catalysts for Telix Pharmaceuticals

Dow Jones

07/15

2305 GMT - Telix Pharmaceuticals' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. "We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus," analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at "buy, high-risk." (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

July 14, 2026 19:06 ET (23:06 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2651748293"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651748293\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651748293?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 07:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651748293","market":"sh","top_or_hot":-1,"title":"Citi Sees Positive Catalysts for Telix Pharmaceuticals","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2305 GMT - <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 19:06 ET (23:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citi Sees Positive Catalysts for Telix Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCiti Sees Positive Catalysts for Telix Pharmaceuticals\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-15 07:06</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2305 GMT - <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 19:06 ET (23:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651748293","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651748293","pubTimestamp":1784070360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2305 GMT - Telix Pharmaceuticals' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\"  Dow Jones NewswiresJuly 14, 2026 19:06 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK7067":"生物科技","TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"花旗看到 Telix Pharmaceuticals 的积极催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX":1.5,"TLX.AU":0.9},"content_text":"2305 GMT - Telix Pharmaceuticals' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\" (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 14, 2026 19:06 ET (23:06 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}